icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
eNq1mE1z2jAQhu/8Co8PvWGDwU3S2mRamrTMJFNKwrTTCyPsJYgKydUHkP76ypg0pCM3jUBHW/Kr1e7q0TtOzjdL4q2AC8xo6reDlu8BzViO6V3qj28vm6f+ea+RLNAK7U3T84Io8r2MICFSvxwNpoCoCL5dX30A/T1wv9fwEjZdQCafzFMSk+ATEvNrVJRzvGTFcO4tQc5ZnvqFktu3XiIk11H01oz/EAXKIAl3b/ZHF5Pu/vskLMX+Q1UJ4FeI3hlFgVppZopzoLKPJNwxfl8Tb8dKG4sRCKZ4BkMk50POVjiH3LjEDBEBVovM1vkN8BUBWS5iFA8X2VJYiaMF2ozg58Ac9Ds92pcb2Ww12ydR1OpGJ504juySxfdSZa6C3kSYTdonceesG4dAwzksdTdgRiyrM2RcIuKoLlj0n7aWo3U4/Hy2/jkWBUH3wUIUtqlCHOlh4BoA7jZS7uCWayQRnbO/9KkiJHxh1OMdMBxFXPKozxSVNdy4HNkmos+ohE19Re1QJze7XsQgjif7i1Ez5odqSnBmCzWNHQVCjkeDeqYdFwfvkYAxd8eDr5jmbC2Oz5n9ujqKvtii0iha8Lw9ic5OX7fj2PoYfddNVHPLXCjOCgg1gbA4BCwDOmOHIkX3pVnqoSuP2JBbt8MyRKDG7zQt+aI78cGeOet1d+eoGjCKfry4tW2QLwr4/c320SiN8/RPae3g64Louh2fC7w6uGkx6bTi07NO9xVaFm8fjHRqaZorUSeeWXEzZeZSFuJNGK7X62CORFMgnc9gxv91D5wbN3+MBGjoPtbTnbF3YgMqW1QB11Ho0+omfVkhbY/uc0bhUPO7+35nso1rSK7ggFpUlHfG4sHF8fH+6HydhT18Ahl3y2xdKpKYUVfeSU2NioddKLqu9JJrQHyezXDNj5bavkzC6idPr5GE5Q+eXuM33SMDiA==
2pSBL2jGH587PFUZ